Status:

TERMINATED

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)

Lead Sponsor:

NICHD Neonatal Research Network

Collaborating Sponsors:

National Center for Research Resources (NCRR)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Conditions:

Prematurity

Respiratory Insufficiency

Eligibility:

All Genders

Up to 7 years

Phase:

PHASE2

Brief Summary

This is a randomized controlled trial (RCT) on the use of Inhaled prostaglandin E1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure (NHRF). Fifty patients recruited at 10 high volume sites within the...

Detailed Description

Hypoxemic respiratory failure in the newborn (NHRF) is usually associated with widespread vasoconstriction of the pulmonary microvasculature giving rise to intra- and extra-pulmonary shunts and profou...

Eligibility Criteria

Inclusion

  • Gestational age less than or equal to 34 weeks
  • Postnatal age less than or equal to 7 days (168 hours).
  • Assisted ventilation for hypoxemic respiratory failure.
  • Diagnosis of NHRF including perinatal aspiration syndrome (meconium, blood, or amniotic fluid), suspected/proven pneumonia/sepsis, respiratory distress syndrome, idiopathic persistent pulmonary hypertension of the newborn (PPHN) or suspected pulmonary hypoplasia.
  • Receiving INO for at least 1 hour and not \>72 hours.
  • Oxygenation Index (OI ) ≥ 15 on any 2 arterial blood gases 15 minutes to 12 hours apart while on INO.
  • An indwelling arterial line is present

Exclusion

  • Any infant in whom a decision has been made not to provide full treatment (e.g. chromosomal anomalies, severe birth asphyxia).
  • Known structural congenital heart disease except patent ductus arteriosus and atrial/ventricular level shunts.
  • Congenital diaphragmatic hernia.
  • Thrombocytopenia unresponsive to platelet transfusion.
  • Enrollment in a conflicting and/or Investigational New Drug (IND) clinical trial.

Key Trial Info

Start Date :

November 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2012

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT01467076

Start Date

November 1 2011

End Date

June 1 2012

Last Update

April 24 2019

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

2

University of California - Los Angeles

Los Angeles, California, United States, 90025

3

Stanford University

Palo Alto, California, United States, 94304

4

University of Iowa

Iowa City, Iowa, United States, 52242